Company

OncoCyte Corporation

Headquarters: Irvine, CA, United States

Employees: 33

CEO: Mr. Ronald A. Andrews Jr.

NYSE: OCX -4.56%

Market Cap

$27.8 Million

USD as of Jan. 1, 2024

Market Cap History

OncoCyte Corporation market capitalization over time

Evolution of OncoCyte Corporation market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of OncoCyte Corporation

Detailed Description

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics, Inc. The company was founded in 2009 and is headquartered in Irvine, California.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

OncoCyte Corporation has the following listings and related stock indices.


Stock: NYSE: OCX wb_incandescent

Stock: FSX: 7OC wb_incandescent

Stock: NASDAQ: OCX wb_incandescent

Details

Headquarters:

15 Cushing

Irvine, CA 92618

United States

Phone: 949 409 7600